Vera Therapeutics, Inc. Stock Price, News & Analysis

Vera Therapeutics has announced the acquisition of MAU868, a first-in-class monoclonal antibody targeting BK Virus (BKV) infections, which is a significant cause of kidney transplant failure. The transaction involves an upfront payment of $5 million and potential milestone payments totaling $7 million. Vera has also secured a $50 million credit facility with Oxford Finance to support further development. MAU868 is currently in a Phase 2 clinical trial, with results expected in mid-2022. This acquisition aligns with Vera’s strategy to enhance its pipeline for immunological diseases.

Vera Therapeutics announces the appointment of Kimball Hall to its board of directors. Hall, with over 30 years of experience in the pharmaceutical industry, is recognized for her leadership roles at Genentech and Amgen, and her current position as president of Abzena, a contract development and manufacturing organization. Her expertise in drug manufacturing and strategic development is expected to enhance Vera's objectives, particularly in advancing its lead clinical candidate, atacicept, aimed at treating serious immunological diseases.

Vera Therapeutics (Nasdaq: VERA), a biotechnology company focused on immunological diseases, announced that its CEO, Marshall Fordyce, will present at several investor conferences in November 2021. These include the Jefferies London Healthcare Conference (November 16-18) and the Evercore ISI HealthCONx (November 30 - December 2). Fordyce's presentations will discuss Vera’s lead product candidate, atacicept, aimed at treating autoimmune diseases. Replay links for all presentations will be available for 30 days on the company’s website.

Vera Therapeutics reported ongoing progress in its Phase 2a JANUS clinical trial for atacicept, showing substantial and durable reductions in serum Gd-IgA1 levels in patients with IgA nephropathy. Key highlights include a 60% reduction in Gd-IgA1 for the 75mg dose, indicating potential for renal survival benefits. Financially, Vera posted a net loss of $7.6 million for Q3 2021, with $86.2 million in cash as of September 30, 2021. The company is advancing the Phase 2b ORIGIN study and awaits FDA feedback on its lupus nephritis development strategy.

The Phase 2a JANUS clinical trial for atacicept, conducted by Vera Therapeutics, demonstrated a significant and durable reduction in serum galactose-deficient IgA1 (Gd-IgA1) over 72 weeks in patients with IgA nephropathy (IgAN). The trial revealed that atacicept 75mg lowered serum Gd-IgA1 levels to the lowest risk quartiles, highlighting its potential to improve renal survival. These findings were presented at the American Society of Nephrology Kidney Week 2021. The company anticipates further results from the ongoing Phase 2b ORIGIN trial to clarify the implications of these reductions on renal function.

Vera Therapeutics announces the upcoming presentation of clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be shared during an ePoster session at the American Society of Nephrology Kidney Week 2021, held virtually from November 4-7, 2021. The presentation, titled 'Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients', will feature critical findings aimed at advancing treatments for this immunological disease.

Vera Therapeutics, Inc. (Nasdaq: VERA) will host a KOL webinar on IgA Nephropathy on September 20, 2021. The event will include presentations by experts Richard Lafayette, M.D., and Jonathan Barratt, Ph.D., focusing on the efficacy of atacicept in treating IgAN. Atacicept targets B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), with promising clinical trial data supporting its potential as a best-in-class therapy. The webinar will allow attendees to ask questions after the presentations.

Vera Therapeutics, Inc. (Nasdaq: VERA) reported its Q2 2021 financial results, highlighting significant clinical and financial advancements. They initiated the Phase 2b clinical trial named 'ORIGIN' for atacicept in IgA nephropathy patients, aiming to establish it as the first disease-modifying therapy for this condition. The company reported a net loss of $3.4 million, with cash and equivalents totaling $91.6 million as of June 30, 2021, bolstered by IPO proceeds. The management team expanded with the appointment of Sean Grant as Chief Financial Officer.

Vera Therapeutics announced the appointment of Sean Grant as Chief Financial Officer, effective immediately. With nearly 15 years in financial services, he brings expertise from CareDx and Citigroup, focusing on strategic investments and capital markets. CEO Marshall Fordyce emphasized Grant's significant experience will enhance the company's financial strategies as it develops its lead candidate atacicept, aimed at treating immunological diseases. Atacicept is expected to help patients with conditions like IgA nephropathy, addressing a market with no existing disease-modifying treatments.